History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019
Conferences
Levintow, SN; Wiener, C; Orroth, KK; Gill, K; Mullard, A; Brookhart, MA; McGrath, LJ
Published in: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
October 2020
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
October 2020
Volume
29
Start / End Page
55 / 55
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Levintow, S. N., Wiener, C., Orroth, K. K., Gill, K., Mullard, A., Brookhart, M. A., & McGrath, L. J. (2020). History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (Vol. 29, pp. 55–55).
Levintow, Sara N., Catie Wiener, Kate K. Orroth, Karminder Gill, Andrew Mullard, M Alan Brookhart, and Leah J. McGrath. “History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019.” In PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 29:55–55, 2020.
Levintow SN, Wiener C, Orroth KK, Gill K, Mullard A, Brookhart MA, et al. History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. In: PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–55.
Levintow, Sara N., et al. “History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019.” PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, vol. 29, 2020, pp. 55–55.
Levintow SN, Wiener C, Orroth KK, Gill K, Mullard A, Brookhart MA, McGrath LJ. History of lipid lowering therapy use among adults initiating treatment with proprotein convertase subtilisin/kexin type 9 antibody inhibitors in the United States, 2015-2019. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY. 2020. p. 55–55.
Published In
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
EISSN
1099-1557
ISSN
1053-8569
Publication Date
October 2020
Volume
29
Start / End Page
55 / 55
Related Subject Headings
- Pharmacology & Pharmacy
- 4202 Epidemiology
- 3214 Pharmacology and pharmaceutical sciences